Department of Cardiothoracic Surgery, Maastricht University Medical Center, MUMC+), P. Debyelaan 25, 6229HX, Maastricht, The Netherlands.
Cardiovascular Research Institute Maastricht (CARIM), University Maastricht, Maastricht, The Netherlands.
Crit Care. 2024 Jul 3;28(1):217. doi: 10.1186/s13054-024-05008-9.
The outcomes of several randomized trials on extracorporeal cardiopulmonary resuscitation (ECPR) in patients with refractory out-of-hospital cardiac arrest were examined using frequentist methods, resulting in a dichotomous interpretation of results based on p-values rather than in the probability of clinically relevant treatment effects. To determine such a probability of a clinically relevant ECPR-based treatment effect on neurological outcomes, the authors of these trials performed a Bayesian meta-analysis of the totality of randomized ECPR evidence.
A systematic search was applied to three electronic databases. Randomized trials that compared ECPR-based treatment with conventional CPR for refractory out-of-hospital cardiac arrest were included. The study was preregistered in INPLASY (INPLASY2023120060). The primary Bayesian hierarchical meta-analysis estimated the difference in 6-month neurologically favorable survival in patients with all rhythms, and a secondary analysis assessed this difference in patients with shockable rhythms (Bayesian hierarchical random-effects model). Primary Bayesian analyses were performed under vague priors. Outcomes were formulated as estimated median relative risks, mean absolute risk differences, and numbers needed to treat with corresponding 95% credible intervals (CrIs). The posterior probabilities of various clinically relevant absolute risk difference thresholds were estimated.
Three randomized trials were included in the analysis (ECPR, n = 209 patients; conventional CPR, n = 211 patients). The estimated median relative risk of ECPR for 6-month neurologically favorable survival was 1.47 (95%CrI 0.73-3.32) with a mean absolute risk difference of 8.7% (- 5.0; 42.7%) in patients with all rhythms, and the median relative risk was 1.54 (95%CrI 0.79-3.71) with a mean absolute risk difference of 10.8% (95%CrI - 4.2; 73.9%) in patients with shockable rhythms. The posterior probabilities of an absolute risk difference > 0% and > 5% were 91.0% and 71.1% in patients with all rhythms and 92.4% and 75.8% in patients with shockable rhythms, respectively.
The current Bayesian meta-analysis found a 71.1% and 75.8% posterior probability of a clinically relevant ECPR-based treatment effect on 6-month neurologically favorable survival in patients with all rhythms and shockable rhythms. These results must be interpreted within the context of the reported credible intervals and varying designs of the randomized trials.
INPLASY (INPLASY2023120060, December 14th, 2023, https://doi.org/10.37766/inplasy2023.12.0060 ).
几项关于体外心肺复苏(ECPR)在难治性院外心脏骤停患者中的随机试验结果使用频率方法进行了检查,导致结果的解释基于 p 值而不是基于临床相关治疗效果的概率。为了确定基于 ECPR 的治疗效果在神经结局方面的这种临床相关概率,这些试验的作者对所有随机 ECPR 证据进行了贝叶斯荟萃分析。
应用系统搜索对三个电子数据库进行了搜索。纳入了比较 ECPR 治疗与常规心肺复苏治疗难治性院外心脏骤停的随机试验。该研究已在 INPLASY(INPLASY2023120060)中预先注册。主要贝叶斯层次荟萃分析估计了所有节律患者 6 个月时神经功能良好存活的治疗效果差异,二次分析评估了可电击节律患者的差异(贝叶斯层次随机效应模型)。主要贝叶斯分析在模糊先验下进行。结果以估计的中位数相对风险、平均绝对风险差异和相应的 95%可信区间(CrI)表示的需要治疗人数。还估计了各种临床相关绝对风险差异阈值的后验概率。
分析纳入了三项随机试验(ECPR,n=209 例;常规 CPR,n=211 例)。所有节律患者中,ECPR 治疗 6 个月神经功能良好存活的估计中位数相对风险为 1.47(95%CrI 0.73-3.32),平均绝对风险差异为 8.7%(-5.0;42.7%),可电击节律患者中,ECPR 治疗的估计中位数相对风险为 1.54(95%CrI 0.79-3.71),平均绝对风险差异为 10.8%(95%CrI-4.2;73.9%)。所有节律患者和可电击节律患者中,绝对风险差异>0%和>5%的后验概率分别为 91.0%和 71.1%,92.4%和 75.8%。
目前的贝叶斯荟萃分析发现,所有节律和可电击节律患者的 6 个月神经功能良好存活的基于 ECPR 的治疗效果具有 71.1%和 75.8%的后验概率。这些结果必须在报告的可信区间和随机试验不同设计的背景下进行解释。
INPLASY(INPLASY2023120060,2023 年 12 月 14 日,https://doi.org/10.37766/inplasy2023.12.0060)。